Compounded Tirzepatide No Longer Available After March 19, 2025
The shortage of tirzepatide injections has made the FDA issue an important update to stop compounding of tirzepatide injections. This drug is known to benefit patients of type 2 diabetes and also support weight loss efforts. The shortage was reported in 2022 due to the increased demand and this order signifies that manufacturers should have … Continue reading Compounded Tirzepatide No Longer Available After March 19, 2025
View More